Corrigendum to “Epidemiology of adult patients with atopic dermatitis in AWARE 1: A second international survey” [World Allergy Organ J 16 (3) (2023) 100724]
Jorge Máspero, Laurent Eckert(Sanofi (France)), E S Fedenko(Federal Medical-Biological Agency), Issam Hamadah(King Faisal Specialist Hospital & Research Centre), Angelina Tsankova, Gloria Sanclemente(Universidad de Antioquia), Kanokvalai Kulthanan(Siriraj Hospital), Norma de Paula Motta Rubini(Universidade Federal do Estado do Rio de Janeiro), Sarah El-Samad, Lysel Brignoli, Özlem Su(Bezmiâlem Vakıf Üniversitesi), Catalina Rincón-Peréz(Ministry of National Defense), Chia‐Yu Chu(National Taiwan University Hospital), Yik Weng Yew(National Skin Centre), Anwar Al-Hammadi(Dubai Medical College), Roni P. Dodiuk‐Gad(Emek Medical Center), Jianzhong Zhang(Chinese Academy of Sciences), Suganthi Thevarajah(Hospital Kuala Lumpur), Mark BY Tang(National Skin Centre), Jose Eduardo Neves(Sanofi (United States)), Alsan Chan Wai Ming(Hong Kong Sanatorium and Hospital), Julio Roberto Amador(Military University Nueva Granada)
Cited by 3
Related Papers
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
|Allergy|2018|1.5k
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
|Allergy|2021|1.2k
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis
|JAMA Dermatology|2019|516